Stock Scorecard
Stock Summary for Citius Pharmaceuticals Inc (CTXR) - $1.26 as of 12/3/2025 3:47:10 PM EST
Total Score
11 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CTXR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CTXR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CTXR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CTXR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CTXR (32 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CTXR
Financial Details for CTXR
Company Overview |
|
|---|---|
| Ticker | CTXR |
| Company Name | Citius Pharmaceuticals Inc |
| Country | USA |
| Description | Citius Pharmaceuticals Inc. (CTXR), headquartered in Cranford, New Jersey, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for critical care environments. The firm is focused on addressing substantial unmet medical needs with a promising pipeline of products aimed at improving patient outcomes in hospital settings. Citius leverages cutting-edge technologies and forms strategic collaborations to position itself as a leader in the critical care sector, contributing to transformative advancements in patient care. With a strong commitment to innovation and a clear strategic vision, Citius presents a compelling investment opportunity in the biopharmaceutical arena for institutional investors. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 12/26/2025 |
Stock Price History |
|
| Last Day Price | 1.26 |
| Price 4 Years Ago | 38.50 |
| Last Day Price Updated | 12/3/2025 3:47:10 PM EST |
| Last Day Volume | 523,087 |
| Average Daily Volume | 866,428 |
| 52-Week High | 5.95 |
| 52-Week Low | 0.65 |
| Last Price to 52 Week Low | 93.85% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.11 |
| Sector PE | 88.06 |
| 5-Year Average PE | -81.49 |
| Free Cash Flow Ratio | 3.82 |
| Industry Free Cash Flow Ratio | 13.81 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 0.47 |
| Total Cash Per Share | 0.33 |
| Book Value Per Share Most Recent Quarter | 4.50 |
| Price to Book Ratio | 0.41 |
| Industry Price to Book Ratio | 33.69 |
| Sector Price to Book Ratio | 33.12 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.75 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.97 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 18,472,200 |
| Market Capitalization | 23,274,972 |
| Institutional Ownership | 13.08% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -20.27% |
| Reported EPS 12 Trailing Months | -4.55 |
| Reported EPS Past Year | -3.37 |
| Reported EPS Prior Year | -1.76 |
| Net Income Twelve Trailing Months | -40,264,787 |
| Net Income Past Year | -39,138,839 |
| Net Income Prior Year | -32,542,912 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 100.57% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 6,089,126 |
| Total Cash Past Year | 3,251,880 |
| Total Cash Prior Year | 26,480,928 |
| Net Cash Position Most Recent Quarter | 5,916,156 |
| Net Cash Position Past Year | 2,914,327 |
| Long Term Debt Past Year | 337,553 |
| Long Term Debt Prior Year | 337,553 |
| Total Debt Most Recent Quarter | 172,970 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 70,077,450 |
| Total Stockholder Equity Prior Year | 90,831,108 |
| Total Stockholder Equity Most Recent Quarter | 65,058,550 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -20,584,640 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.11 |
| Free Cash Flow Past Year | -28,201,375 |
| Free Cash Flow Prior Year | -29,060,214 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.03 |
| MACD Signal | -0.07 |
| 20-Day Bollinger Lower Band | 0.95 |
| 20-Day Bollinger Middle Band | 1.33 |
| 20-Day Bollinger Upper Band | 1.71 |
| Beta | 1.50 |
| RSI | 57.24 |
| 50-Day SMA | 1.63 |
| 150-Day SMA | 14.32 |
| 200-Day SMA | 18.05 |
System |
|
| Modified | 12/3/2025 9:12:32 PM EST |